DP
TRVI icon

Diadema Partners’s Trevi Therapeutics TRVI Stock Holding History

Diadema Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,663
Closed -$258K – 198
2026
Q1 		$258K Sell
21,663
-75,521
-78% -$846K 0.04% 123
2025
Q4 		$1.22M Buy
97,184
+11,354
+13% +$131K 0.21% 87
2025
Q3 		$785K Sell
85,830
-100,000
-54% -$750K 0.2% 92
2025
Q2 		$1.02M Buy
185,830
+5,830
+3% +$36.3K 0.31% 64
2025
Q1 		$1.13M Buy
+180,000
New +$859K 0.3% 62

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Diadema Partners's TRVI Position: Q2 2026 in Review

Diadema Partners sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 21,663 shares — an estimated $258K sold.

Diadema Partners first reported a position in TRVI in Q1 2025 and held it in 5 quarters. The position peaked at $1.22M in Q4 2025. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Diadema Partners reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Diadema Partners sold 21,663 Trevi Therapeutics shares in Q2 2026, an estimated $258K.
  • Diadema Partners first reported a position in Trevi Therapeutics in Q1 2025 and held it in 5 quarters.
  • Diadema Partners's Trevi Therapeutics position peaked at $1.22M in Q4 2025.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.